Sort
4,870 grants matching “glp 1”
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
$1,061,403Christopher D Pack · Metaclipse Therapeutics Corporation · R44 · FY2021 · CA
Development of PAR2 Pepducins as a Novel NASH Treatment
$1,060,598Athan Kuliopulos · Oasis Pharmaceuticals · R44 · FY2018 · DK
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents
$1,060,173Dennis Liang Fei · Stemsynergy Therapeutics, Inc. · R44 · FY2024 · CA
Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A
$1,059,214Gerald W. Dorn · Mitochondria In Motion, Inc. · R42 · FY2021 · NS
Structural Analysis Of Candidate Genes For Type 2 Diabetes and Obesity
$1,059,022Leslie J Baier · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Development of an RNA-based anticoagulant and antidote for precise on/off coagulation control during cardiovascular procedures
$1,058,454Abhichart Krissanaprasit · Helixomer, Inc. · R44 · FY2024 · HL
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae
$1,058,081Zachary David Aron · Microbiotix, Inc · R01 · FY2020 · AI
Neuroprotective Apolipoprotein-E Analogs Continuation
$1,056,457Michael Peter Vitek · Cognosci, Inc. · R44 · FY2009 · AG
Optimizing Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Malaria
$1,056,231Ian Cyril Bathurst · Medicines For Malaria Venture · U01 · FY2007 · AI
Development of PAR2 Pepducins as a Novel NASH Treatment
$1,056,106Athan Kuliopulos · Oasis Pharmaceuticals · R44 · FY2019 · DK
Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease
$1,055,169Jay Williams Hooper · Geneva Foundation · R01 · FY2018 · AI
AAV-mediated gene therapy for GM2-gangliodoses
$1,054,908Miguel S Esteves · Univ Of Massachusetts Med Sch Worcester · U01 · FY2009 · NS
AAV-mediated gene therapy for GM2-gangliodoses
$1,054,908Miguel S Esteves · Univ Of Massachusetts Med Sch Worcester · U01 · FY2009 · NS
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae
$1,052,607Michelle M. Butler · Microbiotix, Inc · R01 · FY2021 · AI
A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS
$1,051,862John Anthony Muraski · Endurx Pharmaceuticals, Inc. · R44 · FY2015 · CA
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections
$1,051,346David S Perlin · Hackensack University Medical Center · R01 · FY2020 · AI
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute
$1,050,000Esma Alp · Kalocyte, Inc. · R44 · FY2023 · HL
Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds
$1,050,000Manav Mehta · Gel4med, Inc. · R44 · FY2025 · AI
Novel biologic to treat chemotherapy-induced neuropathic pain
$1,049,997Yakov Kogan · Raft Pharmaceuticals, Llc · R44 · FY2023 · CA
Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease
$1,049,794Jay Williams Hooper · Geneva Foundation · R01 · FY2020 · AI
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy
$1,049,717Gary Fanger · Rise Therapeutics, Llc · R44 · FY2022 · CA
Arterial-Mimetic Grafts Molded from Purified Proteins
$1,049,677David B Masters · Gel-Del Technologies, Inc. · R44 · FY2009 · HL
Development of PAR2 Pepducins as a Novel NASH Treatment
$1,048,644Athan Kuliopulos · Oasis Pharmaceuticals · R44 · FY2017 · DK
Universal room temperature stable influenza nanovaccine
$1,047,614Balaji Narasimhan · Iowa State University · R01 · FY2021 · AI
Arterial-Mimetic Grafts Molded from Purified Proteins
$1,047,181David B Masters · Gel-Del Technologies, Inc. · R44 · FY2010 · HL